3. Opioid Analgesics Flashcards

1
Q
I. OPIOIDS
A. Phenanthrenes
1. Agonists
a. Naturally-occurring opium alkloids
\_\_\_\_ 
Morphine

b. Semisynthetic derivatives of morphine
____ (DILAUDID) Oxymorphone (NUMORPHAN)

c. Semisynthetic derivatives of codeine
____
Oxycodone (ROXICODONE

  1. Partial Agonist
    ____ (BUPRENEX)
  2. Agonist-Antagonist
    ____ (NUBAIN)
A
codeine
hydromorphone
hydrocodone
buprenorphine
nalbuphine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

B. Phenylheptanes
____ (ORLAAM)
Methadone (DOLOPHINE) ____ (DARVON)

C. Morphinans
1. Agonist
____ (LEVO-DROMORAN)

  1. Agonist-Antagonist
    ____ (STADOL)
A

levomethadyl
propoxyphene

levorphanol

butorphanol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q
D. Phenylpiperidines 
\_\_\_\_ (ALFENTA)
Fentanyl (SUBLIMAZE; DURAGESIC TRANSDERM) \_\_\_\_ (IMMODIUM)
Remifentanil (ULTIVA) 
\_\_\_\_ (DEMEROL) 
Sufentanil (SUFENTA)

E. Benzomorphan
Agonist-Antagonist
____ (TALWIN)

F. Aminotetralin
Agonist-Antagonist
____ (DALGAN)

A

alfentanil
loperamide
meperidine

pentazocine

dezocine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Morphine – ____ occurring chemical

Codeine – also ____ occurring but the difference is a ____ group.

  • DONT prescribe it to any of your ____ patients
  • its demethylated to morphine.. some peds patients died from undergoing a TNA (?).. they were identified as ultra rapid ____.. and died from a morphine blood level
A
naturally
naturally
methyl
pediatric
metabolizers
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Heroin – wanted a better analgesic aka get into the brain faster so they ____ it -Bayer (company that makes aspirin) made it
-rapidly acting and gives a big high, deacetlyated in the brain very quick

Hydromorphone – more ____ and lasts ____ than heroin -1 of the reasons why you cant prescribe heroin/we don’t need it is bc this drug that you can prescribe is even better if needed

A

acetylated

potent
longer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Meperidine - idk any docs prescribing this. I took this off DO boards.
-Not very potent (200-300mg), same group/very similar structure to ____

Methadone – used in ____ (medication assisted treatment) -same category as ____ (Darvon)

A

fentanyl
MAT
propoxyphene

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Full Antagonist
Naloxone (Narcan) – every health professional should carry it, it has overburdened the city healthcare system

Naloxegol – only acting at the ____ level, goal is to block the constipation

Agonist-Antagonist
Pentazocine – sufficiently similar to the opioid receptor but more to the ____ receptor
-drug companies wanted to make a non-____ opioid analgesic.. will never occurs as long as people keep developing addictions

A

peripheral
kappa
addicting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Morphine – don’t really give it IM but this was a study

  • what do these acute values tell us? High first ____ effect (will have to give more) -does that mean we can give morphine PO? ____
  • most ____ used drug around the world for treating pain
  • decrease its dose in cancer patients that start having ____ problems

*”Again im not going to ask you doeses Dr. hersh will tell you which ones you need to know”
Methadone – synthetic, not much of a first ____ effect
-no need to give via Parental, it is given ____ and to cancer pts

Heroin is at 5 when Hydromorphone is 1.5.. so ____ (trade: Dialudid) is more potent than heroin

A

pass
no
widely
liver

pass
PO
hydromorphone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Im not going to ask you to figure this out..

  • FDA is centering around 90 MME/day to be a trigger
  • some docs freaked out bc some pts on more than that.. can develop tremendous tolerance
  • if you have a cancer pt you may have to use the chart
  • remember though the chart conversions are 100% accurate, you have to go ____ than what the chart tells you to be safe
A

lower

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Morphine Mg Equivalents
Do not use calculated dose in ____ to determine dosage for converting one opioid to another.

New opioid should be ____ to avoid unintentional overdose caused by incomplete cross-tolerance and individual differences in opioid pharmacokinetics. Consult medication label.

Dosages at or above ____ MME/day increase risk for OD by at least 2X.

Even relatively low dosages (20-50 MME per day) increase ____.

A

morphine milligram equivalents (MMEs)
lower
50
risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

-Some of the opioids out there are only Kappa compounds -Delta is more endogenous compounds

Morphine on all of these is an ____
Buprenorphine – ____, meaning there’s an upper ceiling to the respiratory depression which is good

____ and other compounds are not good to give to a pt that’s been on an opioid for over a week

Naloxone and Naltrexone are a ____ lasting form

A

agonist
partial agonist
butorphanol
longer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Mu-1
Primary action:
____
Euphoria

Mu-2
Primary action:
\_\_\_\_ 
Respiratory depression
\_\_\_\_
Kappa:
Primary action:
\_\_\_\_
Diuresis 
\_\_\_\_

Delta:
Primary action:
____
Spinal analgesia

A

supraspinal analgesia

spinal analgesia
constipation

spinal analgesia
dysphoria

supraspinal analgesia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Endogenous Opioids
Electrical stimulation of specific CNS areas (e.g., ____) produces strong ____.
Blocked by ____ antagonists.

Reason: presence of endogenous opioids—-> ____ receptors
Effects are very similar to ____ drugs.

A

periaqueductal gray (PAG)
analgesia
narcotic

opioid
narcotic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Endorphins
Presursor: propiomelanocortin ____—-> beta-endorphin

Beta-endorphin:
- 31-amino-acid peptide
- split from larger peptide that also yields ____
and alpha ____ - found primarily in pituitary gland
- binds predominantly to ____ and delta sites
Produce various behavioral and physiological responses to pain

A

propiomelanocortin
ACTH
MSH
mu

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q
Enkephalins
Precursor: \_\_\_\_
Pentapeptides; two types are:
- \_\_\_\_ (met-enkephalin)
- amino acid # 61-65 of beta-endorphin - leucine-enkephalin (leu-enkephalin)

Located in nerve endings throughout CNS (especially ____, dorsal horn - spinal cord, basal ganglia, portions of limbic sys.)

Appear to bind equally to ____ and mu1 sites

Probable mechanism:

  • bind to opioid receptor
  • decrease release of ____
  • reduce transmission of pain signals
A

proenkephalin
methionine-enkephalin

brainstem
delta

substance P

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Dynorphins
Precursor: ____
Located in neurons throughout the brain.
Bind primarily to ____ sites

Endorphins and enkephalins not of clinical value:
- not absorbed ____
- ____ biotransformation (e.g., blood & brain)
Synthetic enkephalins have been produced; are being evaluated.

A

prodynorphin
kappa

p.o.
rapid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Talking about chemical structure below (Fig 3)
When I was in grad school a long time ago there was a scientist named Beckett who proposed an opioid receptor
-people thought why is there a receptor in the brain to a drug that grows in a plant
-he was right bc he had a series of molecules and if they didn’t configure to a certain shape they weren’t really opioids

Point is morphine fits the ____ receptor (enkephalin receptor) – a pentapeptide
-how did they know this – that the opioid poppy would treat pain? By trial and error people learned a lot about plants
-same with the foxglove plant giving Digitalis
Every opioid that you will prescribe comes from the knowledge of this chemical structure -Terraneous (?) in 1978 said we know what this compound is its endorphin
Runners high – so much pain that endorphins are released

A

endorphin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

CNS
Analgesia
Narcotics are powerful analgetics; decrease severe pain

Mechanism of Action
Stimulate ____receptors.

  1. Supraspinal
    Act at ____ receptors in periaqueductal gray (PAG)
    and related areas to stimulate ____ pathways of inhibition.
    Result: dec transmission of pain signals from spinal cord to higher sites.
  2. Spinal
    Stimulate pre-synaptic ____ receptors.
    Reduces availability of ____
    Consequent reduction in release of ____ of pain (e.g., Substance P).
A
opioid / enkephalin/ endorphin
opioid
descending
enkephalin
neurotransmitters
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Mu / Delta
dec ____ activity then dec in intracellular cAMP -> inc ____ efflux -> hyperpolarization -> dec ____ influx -> dec release of sub P

Kappa
skips to dec ____ influx -> dec release of sub P

A

adenylate cyclase
K+
Ca2+

Ca2+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

CNS (continued)
____

Emesis
Narcotics often produce ____ and vomiting
Frequency increases when the patient becomes ambulatory:
Ø narcotics increase sensitivity to ____

Depression of ____

Respiratory Depression
Can be significantly ____; primary cause of death in ____

Therapeutic doses have minimal effect in most pts:
Ø not an issue unless pre-existing ____ problem (e.g., asthma).

A
sedation
nausea
motion
cough reflex
reduced
OD
respiratory
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

CNS (continued)

CV
Hypotension
Direct: depression of ____ center
Indirect: histamine release–> peripheral ____

GI
Hypomotility
Ø Decreased ____
Ø Delayed ____ emptying

Eye
____

Smooth Muscle
Increased tone
Primarily non-vascular smooth muscle 
Ø\_\_\_\_
Ø \_\_\_\_ tract 
Ø \_\_\_\_

Endocrine function
Pts receiving daily opioid therapy for > 1 a month may undergo ____ in cortisol, sex hormones & DHEA.

A

vasomotor
vasodilation

peristalsis
gastric

miosis

GI
biliary
urinary

reductions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

USES
Analgesia
Relief of ____ pain (e.g., cancer, myocardial infarction, burns, fractures, postsurgical trauma)

Chronic use by legitimate patients does NOT cause ____ (psychological dependence).

Physical dependence, however, does develop after relatively short period of ____ use (e.g., one week).

Ultimate degree of physical dependence related to ____ used daily and ____ of use.

A
moderate to severe
addiction
daily
amount
duration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

USES
Most effective dosing schedule in chronic pain, esp. cancer, is to administer doses on ____ schedule (e.g. Q6H ____).

Quality of sleep improves when patients receive ____ analgesia.

Also elevates their mood which, in turn, leads to a better ____ and improved interactions with relatives, friends and members of health care team.

In addition, pain control may also improve such that ____ narcotic is required (can therefore decrease ____).

A
fixed
around the clock
regular
appetite
less
ADRs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Opiophobia

More restrictive narcotic regulations = ____ use of narcotics

Causes

  1. Fear of ____
  2. Narcotic-induced decreased in ____
    - > can dec ability to prepare for ____
  3. Narcotic-induced ____:
    - > dec pain = dec suffering = dec ____ growth
A
less
addiction
cognition
death
analgesia
spiritual
25
Q

USES (continued)
Obstetrical analgesia
Preop (= pre-emptive analgesia]
- ____ effect with general anesthetics
- improved pain relief ____
——————————————–
ALL pts immediately post-op had PCA morphine for ____ hrs (longer if necessary)

Blood levels of morphine: pts receiving morphine 10 minutes before incision (MOR-pre) had ____ blood levels of morphine postop than those pts given saline before incision (SAL-pre):
48 hrs
SAL-pre: ____ ng/mL
MOR-pre: ____ ng/mL

A

synergistic
postop

48
lower
25.11
12.77

26
Q

USES

Nausea and Vomiting: compared to SAL-pre, patients in the MOR-pre group had ____ nausea and vomiting at 36 and 48 hours.

Observer-Reported Pain: nurse-observers reported that pts in both SAL-pre and MOR-pre had ____ analgesia. However, on several occasions, nurses observed that patients in the MOR- pre group had a greater degree of ____ and were able to ____ earlier & more successfully than pts in SAL-pre.

Patient-Reported Pain: patients in both groups reported that they experienced the ____ degree of analgesia.
Obstetrical analgesia

A
decreased
similar
comfort
ambulate
same
27
Q

USES

Other
Relief of ____ (e.g., codeine)

Relief of severe ____

Immediate (and short-term) relief of dyspnea associated with:
Ø ____
Ø left ventricular failure
Ø mechanism: reduction of ____ workload

Improve respiration in pts on ____
(dec tendency of such pts to ‘____’ assisted breathing)

A
non-productive chronic cough
diarrhea
pulmonary edema
left ventricular
mechanical ventilators
fight
28
Q

REMEMBER: ASTERISK MEANS DEVELOPS TOLERANCE!!!

ADRs
CNS
\_\_\_\_* 
\_\_\_\_* 
Disorientation, delirium
Incoordination Transient hallucinations
Agitation, tremor, seizures Euphoria or dysphoria

CV

A

headache, nausea

dizziness, sedation

29
Q
ADRs
 CNS
Headache, \_\_\_\_*
Dizziness, \_\_\_\_*
Disorientation, delirium
Incoordination Transient hallucinations
Agitation, tremor, seizures Euphoria or dysphoria

CV
____, hypotension, flushing, syncope Phlebitis (IV injection only)

A

nausea
sedation
bradycardia

30
Q

ADRs
GI
Dry mouth, anorexia
____:
Ø significant effect even with therapeutic doses
Ø unfortunately, tolerance does not develop
Ø preventive measures include: - increased fluid intake
- dietary fiber
- ambulation where possible
Ø pt may require daily laxatives

Biliary tract spasm
____*

A

constipation

vomiting

31
Q

Respiratory
Respiratory depression*:
Ø major cause of death in ____
Ø observed in ____ after dose to mother

A

OD

newborn

32
Q

Overdose

____ (may see ____ as well)
Hypotension, bradycardia, cardiac arrest
Hypothermia

Oliguria
Pulmonary edema
Severe respiratory depression, coma

Contraindications
Convulsive states
Increased ____
Undiagnosed acute abdominal conditions

A

miosis
mydriasis
intracranial pressure

33
Q

Interactions

READ ME!

A

read

34
Q

WITHDRAWAL REACTIONS

Approx. 12 hrs after last dose
____, rhinorrhea, ____, yawning, chills, piloerection

Approx. 36 hrs after last dose (usually peak) Abdominal ____, muscle aching, nausea, vomiting, diarrhea, ____, and hyperventilation

Most effects end within ____ days

A

lacrimation
sweating

cramping
hyperthermia
3 to 5

35
Q

MORPHINE
Most widely used ____ (USA and world-wide)
____ administration for cancer pain
Also extensively used in ____ (patient-controlled analgesia) pumps for limited periods of pain (e.g., post-op)

Sig. first-pass effect; biotransformed into glucuronides:
• ____
- high affinity for mu receptor
- has ____ activity
- more powerful than morphine
- highly polar molecule
- CSF levels after ____ admin. > than single dose does not readily exit into blood)

A

narcotic
oral
PCA

morphine-6-glucuronide
analgesic
chronic

36
Q

Accumulation of M-6-G may explain difference in potency ratio between acute and chronic situations:

Acute
IM: ____
PO: ____

Chronic
IM: ____
PO: ____

A

10 mg
60 mg

10 mg
20-30 mg

37
Q

In general, when switching a chronic patient from the current opioid to another one:
- calculate dose based upon ____ potency difference
- then ____ dose
- make upward dosage adjustments as necessary
Reason: cross-tolerance is ____ (mech. not established)

Caution: ____ reported with high dose morphine (e.g, 200 mg/hr, IV) may be due to ____

____ release occurs after epidural and intrathecal; - antihistamines not very effective

  • naloxone: effective but can ____ analgesia
  • propofol (subhypnotic): effective + no dec in ____
A

acute
reduce
incomplete

seizures
morphine-3-glucuronide (M3G)

histamine
reduce
analgesia

38
Q

Sustained-release forms – morphine & related opioids:
Morphine:
____ [8- or 12-hr]
Kadian [12- or 24-hr]
____ [24-hr capsule]
Hydromorphone: ____
Oxycodone: ____; Xtampza Oxymorphone: Opana & Opana-ER

Morphine + naltrexone: Embeda [12-hr]

A

MS contin
avinza

exalgo
oxycontin

39
Q

Fentanyl
Same pharmacological profile as ____.

Extremely potent (approximately ____X morphine).

Significantly greater ____ solubility; ____-acting (30 ® 60 min).

Extended action (up to 72 hours) via ____ patch.

Large % (22% in one study) of pts develop ____ (epidural and transdermal).

A
morphine
100
lipid
shorter
skin
pruritis
40
Q

Fentanyl

Contraindications:

  • ____ pain
  • post-____ pain
  • mild or intermittent pain responsive to prn or non-opioids
  • doses > ____ mcg/hr at start of opioid therapy

Transdermal: Duragesic: 12.5, 25, 50, 75, 100 mcg/h delivery Oral Lozenge: Oralet: 100, 200, 300, 400 mcg
Lozenge on a stick: Actiq:200, 400, 600, 800, 1200, 1600 mcg Buccal tablets: Fentora
Buccal film: Onsolis

There is a FDA standard in the Fentanyl label. The patch should only be used when someone is ____. FDA defines an someone who is opioid tolerant if they have been taking 60mg of Morphine (or equivalent) PO daily for one week.

A

acute
operative
25

tolerant

41
Q

Buprenorphine (BUPRENEX)
Strong binding to ____ receptor; hard to ____ with naloxone
Antagonist at ____ receptor

Dose-related depression of ____ (similar to morphine)

SUBUTEX (C-III)- buprenorphine ____ tablet
SUBOXONE (C-III) buprenorphine + ____ SL film & tab

Under Drug Addiction Treatment Act of 2000 (DATA). Rx use
in Tx of opioid dependence limited to physicians who:
• meet certain qualifying requirements AND
• notify Secretary of Health and Human Services of their intent to prescribe this product for Tx of opioid abuse

A

mu
reverse
kappa-opioid

respiration

sublingual
naloxone

42
Q

Methadone (DOLOPHINE)

Good ____ absorption / limited degree of biotransformation

T1⁄2:
- ____ hrs for most pts (up to 60 hrs!)
- ____ hrs in narcotic addicts
(increased plasma proteins; albumin & globulins)

DANGER: duration of ____ > duration of analgesia
Prolongs ____ interval (rec: use other opioid if pt QT >500 ms)

A

p.o.
15
24

respiratory depression
QT

43
Q

Methadone

Uses
Treatment of cancer pain
Use only in ____ patient who will not ____ from prescribed dosage

Pt must have ____-acting opioid as ‘rescue’ med for:
- episodic pain (e.g., for some specific time when pt
will be moved or has to undergo a diagnostic procedure

  • ‘breakthrough’ pain : BTP / if frequent occurrence, pt probably requires upward adjustment of methadone dosage

Treatment of narcotic addiction
Two advantages:
- ____ effectiveness: dec focus on process of injection
- ____ T 1/2: dec need for frequent dosing during day

Mechanism: high doses given to produce ____ to narcotics Best candidate:

  • ____ years old
  • ____ years of addiction
  • ____ other modalities (e.g., therapeutic community)
A

compliant
deviate

p.o.
long

tolerance

18
two
failed

44
Q

Tramadol (ULTRAM; RALIVIA) ____ acting analgesic.

Synthetic analog of codeine with less affinity for ____
receptors

Mechanism of action:

  • ____ receptor agonist
  • blockade of ____ uptake

Provides analgesia equal to codeine but less than ____.

____ chance for abuse or respiratory depression than other opiate agonists.

Only partially reversed by ____.

A
centrally
opioid
mu-opioid
5-HT
acetaminophen
reduced

naloxone

45
Q

Tapentadol (NUCYNTA®)
Limited ____ receptor affinity; significant inhibition of ____ reuptake.

In animal studies, analgesic action only moderately reduced by naloxone; strongly decreased by an ____adrenoceptor antagonist.

Binding to ____ transporter (NET) > than tramadol

Binding to ____ transporter (SERT) < tramadol.

Efficacy = oxycodone in treatment of moderate to severe pain; less ____ ADRs.

Risk for ____ in patients with convulsive disorders.

A
u-opioid
NE
a2
NE
5HT
GI
seizures
46
Q

Loperamide (Immodium®)
Employed to treat gastrointestinal hypermotility.
Acts on ____ receptors; limited entrance to CNS.

NARCOTIC AGONIST-ANTAGONISTS
Activate ____ receptors
Antagonistic activity at ____ receptors
Less respir. depression than with pure narcotic agonists (mu)
Can precipitate withdrawal in patients on ____ agonists

A

peripheral u-opioid
kappa opioid
mu
mu-opioid

47
Q

Pentazocine (TALWIN)
Originally developed as a ‘____’ opioid but both psychological and physical dependence can develop

Causes adverse psychological reactions

  • e.g., nightmares, hallucinations
  • more likely in pts with ̄ hepatic or renal function (pts may 3-10X more unmetabolized drug than normal)
Talwin Nx
For \_\_\_\_ use only 
Contains \_\_\_\_ (0.5 mg)
- no reduction of \_\_\_\_ p.o.
- \_\_\_\_ after injection (&amp; may ppt withdrawal) Combination has significantly decreased \_\_\_\_
A
non-addictive
oral
naloxone
analgesia
antagonist
abuse
48
Q

Butorphanol (STADOL)
____ times more potent than morphine

Increase in respiratory depression NOT parallel to increase in ____ (e.g., degree of respir. depression at 4 mg » 2 mg)

Now available as ____ spray (as well as parenteral)

Butorphanol is a narcotic ____. There is an increase in respiratory depression.

It is not like Morphine or most narcotics where when you increase the dose, you have an increase in respiratory depression.

For Butorphanol, when you increase the dose, the respiratory depression levels off. BUT this is a narcotic agonist antagonist. It has antagonistic properties.

So if you use this in your practice and you have a cancer pt that has been on Morphine for months and you give them Butorphanol, you will most likely precipitate them with ____ reactions.

A

five
dose
nasal
antagonist

49
Q

NARCOTIC ANTAGONISTS

Naloxone (NARCAN)
Derivative of ____

Mechanism:
- blocks \_\_\_\_ receptors
- higher affinity for opioid receptors than narcotics 
- does not \_\_\_\_ receptors
\_\_\_\_-acting: T1⁄2 » 60 min 

Uses:
Treatment of narcotic ____

Narcan Challenge Test:
- determination of presence of narcotics in patient prior to initiation of ____ (TREXAN) therapy.

A

oxymorphone

opioid
activate
short

overdose
naltrexone

50
Q

NARCOTIC ANTAGONISTS

Nalxoone (NARCAN)

Overdose of opioids
-0.4 to 2 mgIV / can be repeated Q2 to 3 min

  • if max dose (10 mg) produces no reversal, pt may be in OD from ____ types of drugs
  • can be given ____ or IM if veins are inaccessible
Postop \_\_\_\_ (partial reversal) - 0.1 to 0.2 mg IV Q 2 to 3 min to endpoint of:
adequate respiration and \_\_\_\_

Caution: too rapid reversal can produce N, V, increase in ____

FDA-approved forms:
____, intranasal spray (Narcan; Adapt Pharma) autoinjector (Evzio; Kaleo)

A
other
SC
respiratory depression
analgesia
BP
injectable
51
Q

NARCOTIC ANTAGONISTS (continued)

Naltrexone (VIVITROL; DEPADE)
Similar to naloxone; derivative of ____

Used in treatment of narcotic ____

____-acting than naloxone + ____-dependent:

50 mg: peak blood level (p.o.) » 90 minutes
blocks effects of 25 mg heroin, IV, for ____ hrs
100mg: “ “””” ““____”
150mg: “ “””” ““____”

A

oxymorphone
addication
longer
dose

24
48
72

52
Q

NARCOTIC ANTAGONISTS (continued)

Naltrexone (VIVITROL; DEPADE)

Initiation of therapy:
Ø pt must be opioid-free for approximately ____ days
Ø Narcan challege must produce a ____ reaction

IV

  • total dose is ____ mg
  • first give 0.2 mg IV
  • if no withdrawal signs within 30 sec, give remainder (0.6 mg)
  • observe pt for 20 min

SC
- total dose is ____ mg - observe pt for 45 min

PO
- total dose is ____ mg - observe pt for 60 min

Ø if no ____ signs, pt may be started on naltrexone

A

7-10
negative

0.8
0.8
25

withdrawal

53
Q

Naltrexone (VIVITROL; DEPADE)

ADRs include:
____:
- especially at doses of 300 mg and higher
- ____ Therapeutic Index

Confusion
Hallucinations

Contraindications
Pts receiving--or physically dependent upon--opioids 
Pts in withdrawal
Pts with \_\_\_\_ urine test for opioids
Acute hepatitis or liver failure
A

hepatotoxic
narrow
positive

54
Q

Naltrexone (VIVITROL; DEPADE) continued)

Use in treatment of ____

Theory (supported by preclinical and clinical data):
Ø ethanol ­increases cerebral blood flow in right prefrontal cortex
- probable mechanism: ethanol-induced increased release of ____ within frontal cortex-thalamus-limbic
system loop
- may explain ethanol-induced euphoria

Ø naloxone ____ ethanol-induced increased­ in cerebral blood flow
Ø naloxone did not decrease ethanol-induced ____ in all subjects in a limited study (6 subjects; only 2
reported a decrease)

A

alcoholism
endorphins
decreases
euphoria

55
Q

Naltrexone (VIVITROL; DEPADE) continued)

Most commonly reported effect of naltrexone: decrease in ____ use
Ø fewer drinks per day
- alcoholic beverages tasted less pleasant - experienced less of a ‘high’ from alcohol
Ø improved compliance
Ø reduced relapse
- lower dropout rate
- longer time to relapse
Ø more successful in coping with relapse when it occurred

A

alcohol

56
Q

Naltrexone (VIVITROL; DEPADE) continued)

Other reported effects include:
Ø ____
Ø anorexia
Ø weight ____ (during chronic use)

A

dysphoria

loss

57
Q

Naltrexone (VIVITROL; DEPADE) continued)

Possible Mechanisms (based upon clinical data)
1. Enhancement of ____ effects of alcohol (less alcohol needed to obtain desired effect)
Pharmacodynamic effect: probably not
Pharmacokinetic effect: probably not (see #2)

  1. Alteration of alcohol ____
    (higher blood alcohol concentration [BAC] achieved with lower amounts of alcohol) Does ____ appear to occur.
  2. Enhancement of alcohol-induced ____ (negative effects)
    Probably ____
    1. Reduction of alcohol-induced ____ (positive
      reinforcing effects) (desired effect is extinguished)
      Most ____ mechanism (pharmacodynamic)
A

positive
pharmacokinetics
not

dysphoria
not

euphoria
probable

58
Q

Naltrexone (VIVITROL; DEPADE) continued)

ADRs
Same as with use in treating narcotic addiction + increased ____ and vomiting
- may explain reports of anorexia and weight loss

A

nausea

59
Q

Peripheral-acting μ-receptor antagonists.
For treatment of opioid-induced gastrointestinal hypomotility.

SC: ____ (Relistor®)
PO: ____ (Entereg®)BID // ____ (Movantik®) Once/day

A

methylnaltrexone
alvimopan
naloxegol